GlassScriptPhysician profile
Amanda June Basham
NPI 1780326454
$1,405.86
in general payments reported to CMS, 2019-2025
11 companies · $509 in 2025
The $509 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $350 · 2024: $425 · 2025: $509.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,284.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $348.73 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $312.56 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $293.64 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $107.15 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $96.86 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $92.56 | 2023-2025 | |
| Glaxosmithkline, LLC. | $62.17 | 2023-2025 | Trelegy Ellipta |
| Amgen INC. | $32.48 | 2023 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $27.71 | 2022 | |
| Azurity Pharmaceuticals, INC. | $17.00 | 2025 | Azmiro |
| Acerus Pharmaceuticals Corporation | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Basham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.